

What Should Physician Assistants Know about Genetics & Genomics?

Bruce R. Korf, M.D., Ph.D.

Department of Genetics


University of Alabama at
Birmingham

“Genetics can truly claim to be the central basic science of medicine at the beginning of the 21st century.”

- Francis S. Collins, M.D., Ph.D.
Director, National Human Genome Research Institute




editorial *Genetics in Medicine* 1:3, 1998.



- 14% internists and ob/gyn did not know that risk is increased
- 75% would provide counseling
- 9% refer to geneticist, 15% to oncologist or surgeon, 22% call colleague

Hayflick, S.J., et al. Genetics in Medicine 1: 13-21, 1998



- 57% internists and ob/gyn did not know that risk is increased
- 55% would provide counseling
- 9% refer to geneticist, 15% to oncologist or surgeon, 22% call colleague

Hayflick, S.J., et al. Genetics in Medicine 1: 13-21, 1998

Psychiatric Genetics: A Survey of Psychiatrists' Knowledge, Opinions, and Practice Patterns

Christine T. Finn, M.D.; Marsha A. Wilcox, Sc.D., Ed.D.; Bruce R. Korf, M.D., Ph.D.;
Deborah Blacker, M.D., Sc.D.; Stephanie R. Racette, M.A.;
Pamela Sklar, M.D., Ph.D.; and Jordan W. Smoller, M.D., Sc.D.

J. Clin. Psychiatry 2005;66:821-830.

Statement	Agree, %
I feel competent to discuss genetic information regarding psychiatric illness with patients and their families	23
I feel it is my role to discuss genetic information regarding psychiatric illness with patients and their families	83
My medical training has prepared me to discuss genetic information regarding psychiatric illness with patients and their families	15






DNA sequence → RNA → protein → metabolites
Genome → Transcriptome → Proteome → Metabolome
\$ = Econome

Human Genome Classical Perspective

Genome Organization



Biological Pathways



Transcriptional Regulation


Metabolic Networks

Human Genome Modern Perspective



Monogenic

- sickle cell
- cystic fibrosis
- Huntington




Multifactorial

- asthma
- hypertension
- diabetes



Pharmacogenomics

- drug metabolism
- new drug targets



Cancer

- familial
- sporadic


Human “Phenome”

PROSPECTS

A Tale of Two Drugs Hints at Promise for Genetic Testing

By GINA KOLATA
Published: July 11, 2006

A decade or so ago, when the revolution in [genetics](#) was getting under way, the air was heady with promises.



Bob Kutys/International Registry of Pathology

IN CONTRAST A failed heart, left, and a normal one. Genetic tests might be used to identify patients who can be helped by certain drugs.

Gene tests, scientists predicted, would become an integral part of drug prescribing. No longer would patients find out too late that a drug did not work for them. No longer would they have to wait to see if they had side effects to one drug before switching to another.

Tests of their genes would make all of this clear. But the exception of a few tests for genes on certain cells, the genetics revolution has not yet happened.

The New York Times

Saved by a drop of blood

Posted 7/10/2006 10:57 PM ET

E-mail | Save | Print | Reprints & Permissions | Subscribe to stories like this [RSS](#)

By Rita Rubin, USA TODAY

■ SCREENING TESTS BY STATE

Screening for 29 medical conditions

Iowa
Maryland
Mississippi
New Jersey
Virginia
Washington, D.C.

More than 20 conditions

Alaska
Arkansas
California¹
Connecticut
Florida¹
Idaho
Illinois
Indiana
Kentucky
Maine

Thanks to a persistent nurse, Giana Swift's parents only have to worry about whether she should go to public or private kindergarten — not whether she'll be healthy enough to even go to school.

Analysis of a drop of blood taken from her heel revealed that Giana — which means "God is gracious" — has a rare metabolic disorder called 3MCC for short. She can't metabolize leucine, an amino acid found in protein foods.

When Giana was born in Los Angeles in October 2002, dad David Swift says, California routinely screened newborns for only four disorders, none of them 3MCC. But, he says, a nurse persuaded him and his wife to take part in a pilot project of expanded newborn screening.

California now routinely screens for more than 20 of the 29 disorders recommended by the American College of Medical Genetics, says the March of Dimes' latest newborn-screening



Genetics in the News

DNAdirect Your Genes In Context Register Login

search... GO >

[Benefits of Testing](#) [Genetic Testing](#) [Resource Center](#) [For Professionals](#) [Health Tools](#) [About Us](#)

We Offer Genetic Testing Direct to You

Using only [CLIA-certified](#) reference labs - just like major medical centers.



Family History

If it runs in your family, it doesn't have to be your destiny. Find out if genes are really involved – and what you can do about them.

[Learn More >](#)



Fertility & Pregnancy

Looking for carrier screening? Having difficulty getting pregnant?

[Learn More >](#)



Lifestyle Issues

If you carry certain genes, you can take steps to live longer and healthier.

[Learn More >](#)



Signs & Symptoms

Do you have a chronic, undiagnosed condition? It could be genetic.

[Learn More >](#)



Ethnic Risks

Are you more or less likely to carry certain disease-related genes?

[Learn More >](#)



Easy as 1-2-3

You can order from us, or we can work with your doctor. It's your choice.

[How Testing Works >>](#)



Medical Expertise at Your Convenience

When you test with DNA Direct, you receive personalized information for you and your doctor. [Learn More >>](#)



best DNA tests **Good Housekeeping**

Breast cancer
People who have an abnormality in one of the new breast cancer genes (BRCA1 and BRCA2) need to be on the lookout for breast cancer.

[New Tests for Drug Metabolism](#)

[Listen to NPR's Tech Nation interview with DNA Direct's](#)

Direct to Consumer Genetic Testing



Quality

Professionalism


Evidence-Based Medicine

Genomics

Personalized Medicine


What Should Physician Assistants Know About Genetics?

- 1.
- 2.
3. Family history can be a clue to risk.



Hemochromatosis

- Excessive Fe absorption
- Fe overload in tissues
 - cirrhosis
 - diabetes mellitus
 - heart failure
 - bronzing of skin
 - hypogonadotropic hypogonadism
 - more severe manifestations in males
- Treat with phlebotomy
 - 1 pt = 250 mg Fe




VARIABLE	CLINICALLY UNSELECTED HOMOZYGOUS RELATIVES OF PROBANDS (N=214)	
	MEN	WOMEN
No. of subjects	113	101
Liver biopsies — no. of subjects	78	40
Disease-related conditions — no. of subjects*		
Cirrhosis	14	2
Fibrosis	13	4
Aminotransferase elevation	11	2
Arthropathy	5	2
Subjects with at least 1 disease-related condition — no. (%)	43 (38)	10 (10)
Other clinical findings — no. of subjects		
Diabetes	3	5
Hypogonadotrophic hypogonadism	4	0
Cardiac arrhythmia†	10	3
Portal hypertension with splenomegaly	9	2
Hepatocellular carcinoma	2	0
Porphyria cutanea tarda	1	1

*If a subject had more than one of the finding only the condition listed first.

†Arrhythmia was documented by electroc

Legal Precedents


- Pate v. Threkel, 1995
 - Pate discovered she had medullary thyroid carcinoma 3 years after her mother was treated for disease. She sued physician arguing he had a duty to warn her mother of genetic transmission and recommend testing children.
 - Court found no duty to warn children directly, but did find duty to warn the patient about familial implications
- Safer v. Estate of Pack, 1996
 - Safer's father tx for colon cancer associated with adenomatous polyposis coli. Two decades later, once she was diagnosed with colon cancer, she sued her father's physician's estate for a failure to warn.
 - Court upheld a duty to warn those at-risk of avoidable harm from genetic disease




What Should Physician Assistants Know About Genetics?

- 1.
2. Clinical decisions will increasingly rely on the results of genetic tests.
3. Family history can be a clue to risk.

- = Breast
- = Lung
- = Prostate
- = Ovarian
- = Leukemia



Breast Cancer Prevention



The New England
Journal of Medicine

Copyright © 2002 by the Massachusetts Medical Society

VOLUME 346

MAY 23, 2002


NUMBER 21



RISK-REDUCING SALPINGO-OOPHORECTOMY IN WOMEN
WITH A BRCA1 OR BRCA2 MUTATION

NOAH D. KAUF, M.D., JAYA M. SATAGOPAL, Ph.D., MARK E. ROBSON, M.D., LAUREN SCHUBER, M.S.,
MARTIN HENSLEY, M.D., CLIFFORD A. HUDIS, M.D., NATHAN A. ELUS, Ph.D., JEFF BOYD, Ph.D., PATRICK I. BORGON, M.D.,
RICHARD R. BARAKAT, M.D., LARRY NORTON, M.D., AND KENNETH OHTS, M.D., M.P.H.

GeneTests.org

Home Page	About GeneTests	 GeneReviews	Laboratory Directory	Clinic Directory	Educational Materials
---------------------------	---------------------------------	---	--------------------------------------	----------------------------------	---------------------------------------

Funded by the
National Institutes of Health



09/13/05

309 *GeneReviews*
1,052 Clinics
585 Laboratories testing for
1,162 Diseases
860 Clinical
302 Research only

[More usage statistics](#)

[Administrative Use](#)

(For Laboratory/Clinic
Contacts, User Groups)

Welcome to the **GeneTests** Web site, a publicly funded medical genetics information resource developed for physicians, other healthcare providers, and researchers, available at no cost to all interested persons. Use of this Web site assumes acceptance of the [terms of use](#).

At This Site

- ▶ **GeneReviews**
Online publication of expert-authored disease reviews
- ▶ **Laboratory Directory**
International directory of genetic testing laboratories
- ▶ **Clinic Directory**
International directory of genetics and prenatal diagnosis clinics
- ▶ **Educational Materials**
 - [Illustrated glossary](#)
 - [About genetic services](#)
 - [PowerPoint® slide presentations](#)

What's New

[New Features](#)

- ▶ **Revision History section added to *GeneReviews***

[New in *GeneReviews*](#)

[New Lab Listings](#)


- ▶ **18 new listings**

Genetic Variation

CCCCAGCCTCCTTGCCAACGCCCCCTTTCCCTCTCCCCCTCCCGCTCGGC
GCTGACCCGCCATCCCCACCCCGTGGGAACACTGGGAGCCTGCACTCCA
CAGACCCTCCGCTTCCCTCACCTCAGCCTCCGCTCCCCGCCCTC
TTCCGGCCGAGGGGGCCGGCCCAACCTTCCCTCCCGCCCGCCCGCC
GCGGGGAGGATGGCCGGCCACAGCCCGTGGAAATGGGTCCAGGCCGT
GGTCAGCCCTCCAGGAGCAGCTTCCATAAAAAACAGGACAGCAGAACA
CACATACAGCAGTACTGAGCACAACAAGGAATGTCTAATCAATATTC
CAAATACAGTCTTTGGTTATAAGCGGCCCTCACTACTATTTAAAGAATG
TTAACAAATGAAATATTTGGAGAAGCTGCTGAAAAAATTTATAATCTCT
CAGTTGAAATATTTGATACACTGGAAAAATGTCTTGGTGGCAACAAAAG
GACACAAGAAATAGATGAAACGATGCTGGTCAAACAGTCTGTGCACAAA
ATCTGCCATTTCTTACACCTGTCGTGAAGGAAACCAGCATGCAGCTGAA
CTTCGGAAATGAGCTGGGGTTTTATTTCTCTCAGCTGCAACAATTCA
ATGCAGTCTTACGATTTTACCAGGTTACAGGAATTAAGTGTGTGTC
AGAAGACAATGTTGATTTTCATGATATAGAATTGTTACACTATATCAATGTG
GATTGTGCAAAATTAACGACTCCTGAAGGAAACAGCATTAAATTTAAG
CCCTAAAGAAAGTTGCGCAGTTAGCAGTTATAAATAGCCTGGAAAAAGGCAT
TTTGGAAATGGGATAGAAATATCCAGATGAATTTACAAAACCTGACAGAT
CCCACAGACTGATATGGCTGAATGTGCAGAAAAGCTATTTGACTTGGTGA
TGGTTTTGTTGAAAGCACCAAACGTAAGCAGCAGTTTCCCACTACAAT
CATTCTCCTTATCTTGTCCAGAAAATAATCCAGGATATTTCAAAGACCTG
GTTGATGAAAAACAACATGAATTAAGAAGTTATTTCTGGTAAATCCGAAAG
CTCTTGTGGCCATGGGAAAGGAGGAGCTGACAAATTTGCAATTTCAAT
GCCTGTGTCAAATGTAAGTACTTACATTTTCACTTTTCACTTTTCACT
CTGTCATTTTCACTTTTCCATGGTGGTCACTTTTCACTTTTCACTTTTCACT
TTTTAATCCAAAGTAAGCAATTTCTCAAGAGGCAGTCAACCTTTTCACTTT
TCTAATGTTAAGTGGCTTTTCTTCCGATTTTCACTTTTCACTTTTCACTTT
CAACACTTTAAGATCTTTTGGCTCAGAATTCATTTCTAGAAATCACTATG
TGCTGGTAAATCACCTTTTCAATCATCACCTTTTCACTTTTCACTTTTCACT
GCCTAAGATTTGATGCTTTTATTGTCACTTTTCACTTTTCACTTTTCACTTT
GGTGAACACTTCAATGCAAGTGGCAAGTTTGGAGCAATTTGCAATA
CGAATGGCACGGAGTCAATTTAAAGATTTTCACTTTTCACTTTTCACTTTA
AAGAAAAACCTACAGACCTGGAGACAAGAAGCTATAAGTATCTTCTTGTG
CATGGTGAACCTAATTCATGCAGATCCAAAGCTCTTGTCTTGTAAATCCAAGA
AAACAGGGGCCCGAAACCCAAGGCAGTACAGCAGAATTAATTACAGGGCT
CGTCCAACCTGGTCCCTCAGTCACACATGCCAGAGATTGCTCAGGAAGCAAT
GGAGGCTCTGCTGGTTCTTTCATCAGTTAGATAGCATTGATTTGTGGAATCCT
GATGCTCCTGTAGAAAACATTTTGGGAGATTAGCTCACAAATGCTTTTTTACA
TCTGCAAGAAAATTAACCTAGTCATCAAATGCTTAGTAGCAGACAGAATTTCAA
GTGGTTGCGGGAAATATTGATCTGCAGGAATAAATTTCTTCTTAAAAATAAG
CAGGCAGATAGAAGTTCTGTCACTTTT


CCCCAGCCTCCTTGCCAACGCCCCCTTTCCCTCTCCCCCTCCCGCTCGGC
GCTGACCCGCCATCCCCACCCCGTGGGAACACTGGGAGCCTGCACTCCA
CAGACCCTCCGCTTCCCTCACCTCAGCCTCCGCTCCCCGCCCTC
TTCCGGCCGAGGGGGCCGGCCCAACCTTCCCTCCCGCCCGCCCGCC
GCGGGGAGGATGGCCGGCCACAGCCCGTGGAAATGGGTCCAGGCCGT
GGTCAGCCCTCCAGGAGCAGCTTCCATAAAAAACAGGACAGCAGAACA
CACATACCAAAAGTCAAGTCTGAGCACAACAAGGAATGTCTAATCAATATTC
CAAAACAAGTTTCTTTGGTTATAAGCGGCCCTCACTACTATTTAAAGAATG
TTAACTAAAGAGAAATTTGGAGAAGCTGCTGAAAAAATTTATATCTCTCT
CAGTTGAAATATTTGATACACTGGAAAAATGTCTTGGTGGCAACCAAAG
GACAACAATGAGATTAGATCAACGATGCTGCTCAAACAGTTGCTGCCAGAA
ATCTGCCATTTCTTACACCTGTCGTGAAGGAAACCAGCATGCAGCTGAA
CTTCGGAAATTTCTGCTCTGGGTTTTATTTCTCTCAGCTGCAACAATTCA
ATGCAGTCTTACGCTCTTCTACCAGGTTACAGGATTAAGTGTGTGTC
AGAAGACAATGTTGATTTTATGATAAGAATTGTTAAATTTAATCAATGTG
GATTGTGCAAAATTAACGACTCCTGAAGGAAACAGCATTAAATTTAAG
CCCTAAAGAAGGTTGGCAGTTAGCAGTTATAAATAGCCTGGAAAAAGGCAT
TTTGGAAATGGGATAGAAATATCCAGATGAATTTACAAAACCTGACAGAT
CCCACAGACTGATATGGCTGAATGTGCAGAAAAGCTATTTGACTTGGTGA
TGGTTTTGTTGAAAGCACCAAACGTAAGCAGCAGTTTCCCACTACAAT
CATTCTCCTTATCTTGTCCAGAAAATAATCCAGGATATTTCAAAGACCTG
GTTGATGAAAAACAACAAGTAAGAAGTTATTTCTGGAAAGTAAAGAAAG
CTCTTGTGGCCATGGGAAAGTAGGCAGCTGACAAATTTGCAATTTCAAT
GCCTGTGTCAAATGTAAGCAAGTACTTACATTTTCACTTTTCACTTTTCACT
CTGTCATTTTCACTTTTCCATGGTGGTCACTTTTCACTTTTCACTTTTCACT
TTTTAATCCAAAGTAAGCAATTTCTCAAGAGGCAGTCAACCTTTTCACTTT
TCTAATGTTAAGTGGCTTTTCTTCCGATTTTCACTTTTCACTTTTCACTTT
CAACACTTTAAGATCTTTTGGCTCAGAATTCATTTCTAGAAATCACTATG
TGCTGGTAAATCACCTTTTCAATCATCACCTTTTCACTTTTCACTTTTCACT
GCCTAAGATTTGATGCTTTTATTGTCACTTTTCACTTTTCACTTTTCACTTT
GGTGAACACTTCAATGCAAGTGGCAAGTTTGGAGCAATTTGCAATA
CGAATGGCACGGAGTCAATTTAAAGATTTTCACTTTTCACTTTTCACTTTA
AAGAAAAACCTACAGACCTGGAGACAAGAAGCTATAAGTATCTTCTTGTG
CATGGTGAACCTAATTCATGCAGATCCAAAGCTCTTGTCTTGTAAATCCAAGA
AAACAGGGGCCCGAAACCCAAGGCAGTACAGCAGAATTAATTACAGGGCT
CGTCCAACCTGGTCCCTCAGTCACACATGCCAGAGATTGCTCAGGAAGCAAT
GGAGGCTCTGCTGGTTCTTTCATCAGTTAGATAGCATTGATTTGTGGAATCCT
GATGCTCCTGTAGAAAACATTTTGGGAGATTAGCTCACAAATGCTTTTTTACA
TCTGCAAGAAAATTAACCTAGTCATCAAATGCTTAGTAGCAGACAGAATTTCAA
GTGGTTGCGGGAAATATTGATCTGCAGGAATAAATTTCTTCTTAAAAATAAG
CAGGCAGATAGAAGTTCTGTCACTTTT

Genetics in Medicine



Genetics Dashboard






What Should Physician Assistants Know About Genetics?

1. **A new medical paradigm will emerge.**
2. Clinical decisions will increasingly rely on the results of genetic tests.
3. Family history can be a clue to risk.


Medicine in Transformation

Two Convergent Forces

Information Technology



Genetics




Administer the right
dose of the right
treatment to the right
person at the right time.

“Personalized Medicine”

- Predictive testing and prevention
- Stratification of disease and targeted treatments
- Pharmacogenetics & Pharmacogenomics


α_1 -Antitrypsin Deficiency

- Inhibitor of neutrophil elastase
- Pulmonary emphysem
- Hepatic cirrhosis
- 1:2,500 Caucasians
- Carrier frequency 0.03



J K Stoller and L S Aboussouan, *Thorax* 2004;**59**:708-712

Targeted Therapy



19

20



21

22

X


Y

N Engl J Med 2001; 344:1084-1086, Apr 5, 2001.





Genomic Analysis

EGFr Mutation and Gefitinib Sensitivity in NSC Lung Cancer




NSCLC response to gefitinib




N Engl J Med 2004;350:2130.

Disease Stratification Targeted Therapy



Pharmacogenetics


- CYP2D6 (debrisoquine hydroxylase)
 - Poor metabolizer (PM)
 - Mutations that decrease expression
 - 5-10% N.A. whites; 1-2% African Americans
 - Ultrarapid metabolizer (UM)
 - Duplications
 - 5-10% whites, 29% Ethiopians




Drugs Metabolized by CYP2D6

Class	Examples
Analgesics	Codeine, hydrocodone, tramadol
Antiarrhythmics	Encainide, flecainide, mexiletene, propafenone
Antidepressants	Amitriptyline, desipramine, fluoxetine, fluvaxamine, imipramine, nortriptyline, paroxetine
Antihistamines	Chlorpheniramine, diphenhydramine, promethazine
Antipsychotics	Haloperidol, perphenazine, thiridazine
Beta Blockers	Carvedilol, metoprolol, propranolol, timolol
Cough suppressants	Codeine, dextromethorphan

Warfarin Pharmacogenetics




pharmacokinetics



pharmacodynamics

Drug Toxicity


Potassium flux



Polymorphism in KCNE2 potassium channel (1.6%) found in patient who developed prolonged QT while treated with Bactrim


Sesti F, et al. Proc. Natl. Acad. Sci. (USA) 2000;97:106133-10618.

Pharmacogenetic Testing



Evans WE, Relling MV. Science 1999;286:487-491.

Imagine personalized medicine... the era of matching the right patient with the right treatment is dawning...



Imagine personalized medicine... the era of matching the right patient with the right treatment is dawning...

Revolution Through Competition.

▶ JOIN THE REVOLUTION
▶ X PRIZE Membership

X PRIZES

- ▶ [What is an X PRIZE?](#)
- ▶ [Why X PRIZES Work](#)
- ▶ [Ansari X PRIZE](#)
- ▶ Archon X PRIZE for Genomics
- ▶ [Automotive X PRIZE](#)
- ▶ [Future X PRIZES](#)



The era of personalized medicine is dawning

As scientists gain knowledge from mapping the Human Genome, they will also find new ways to treat and even prevent disease. To build the library of information necessary to advance the field of genomic medicine, it is imperative that we develop DNA sequencing technology that is faster and affordable.

To stimulate breakthrough innovation in the field of genomic sequencing, the X PRIZE Foundation has launched a global competition with a \$10 million prize for the winner of the [Archon X PRIZE for Genomics](#).

Learn more about the [Archon X PRIZE for Genomics](#).

The \$1,000 Genome Sequence

Patient [redacted] Acct #: PA00001111 - SSN: 456-45-4567 - DOB:01/01/60 - Age: 44
In-House Provider: Costello, John B - Primary Care Provider: Anstey, Joseph G - Referring Provider: Zalewski, John F
Patient Phone: 314-555-1111 314-555-2222 - Patient Email: n/a

- Visit
- Front Office
- Billing
- Attachments
- Handouts
- Stored Data
- Transcription
- System

Your patient is a slow metabolizer of azathioprine.

Clinical Summary

Chief Complaint / History of Present Illness

(Type, use auto-fill data, or drop in dictation. You can use this section for CC/HPI or the entire visit note.)

Note Autofill: [dropdown] [Use Data from Last Visit](#)

CCHPI Autofill:	Cough	Use Data from Last Visit
Chief Complaint:	Cough	
Location:		
Quality:	Moderate	
Severity:	Some sputum production	
Duration:	4 weeks	
Timing:		
Context:		
Modifying Factors:		
Assoc. Signs/Symptoms:		


ROS

Choose Autofill: Complete ROS [dropdown] [Use Data from Last Visit](#) [Clear All ROS Fields](#)

General:	No weight loss, night sweats, fatigue
Skin:	No rash, itching jaundice, changes in pigmentation or texture, nails, psoriasis
Head:	No headache, dizziness, trauma
Ears:	No hearing loss, earache, tinnitus, discharge
Eyes:	No difficulty seeing, inflammation, diplopia, lacrimation

The future of healthcare?





Report I
**Learning Objectives for
Medical Student Education**
Guidelines for Medical Schools


Medical School Objectives Project
January 1998

	Clinical Years Now	Residency 5 years +	Practice 10 years +
Prevention	<ul style="list-style-type: none"> • Newborn screening for inborn errors of metabolism and other disorders • Carrier screening for hemoglobinopathies, lysosomal storage disorders, cystic fibrosis • Presymptomatic testing for breast, ovarian, colon cancer • Limited proteomic screening for cancer 	<ul style="list-style-type: none"> • Expanded newborn screening with tandem mass spectrometry • Increased number of prenatal carrier screens • Expanded scope of cancer screening and presymptomatic testing • Limited use of screening panels for common disorders, such as cardiovascular disease or dementia 	<ul style="list-style-type: none"> • Wide array of disorders subject to newborn screening • Routine use of proteomic screens for very early detection of common cancers • Increasing use of screening for risk for common disorders to achieve risk stratification and implement prevention strategies
Diagnosis	<ul style="list-style-type: none"> • High resolution cytogenetic analysis for constitutional changes and cancer • Molecular diagnostic tests for limited number of monogenic disorders • Prenatal diagnosis by amniocentesis and CVS 	<ul style="list-style-type: none"> • Use of microarrays to diagnose subtle chromosomal abnormalities • Increasingly routine use of molecular testing for wide range of monogenic disorders • Increasing use of expression microarrays in histopathological diagnosis • Use of new modes of prenatal testing, such as preimplantation testing 	<ul style="list-style-type: none"> • Use of panels of molecular tests to stratify common disorders such as asthma or hypertension • Routine molecular characterization of tissues in pathology • Use of panels of tests to achieve precise diagnosis of monogenic and chromosomal disorders
Treatment	<ul style="list-style-type: none"> • Limited pharmacological treatment of monogenic disorders (e.g., lysosomal disorders) • Limited use of pharmacogenetic testing (e.g., TPMT) • New forms of chemotherapy based on knowledge of cancer biology • Experimental gene therapy protocols 	<ul style="list-style-type: none"> • Increasing array of monogenic disorders amenable to treatment • Expanded panel of pharmacogenetic tests (e.g., CYP2D6) • Increasing number of new cancer-specific therapies • Continued experimentation with gene therapy • Use of expression arrays to determine treatment strategies for certain diseases 	<ul style="list-style-type: none"> • Routine use of pharmacogenetic profiling • Stratification of common disease and selection of specifically targeted therapies • Limited routine use of gene therapy • Use of expression arrays to determine treatment strategies widespread


Pedagogy

- Genetics is a natural integrator
- Teach things that matter
- Recognize the importance of roll models

2002




2007




J.L. is admitted to the hospital. He rules out for myocardial infarction by enzymes and electrocardiography. Family history reveals two siblings who died suddenly and a child who has had a syncopal episode. Blood is sent for a DNA test and J.L. is found to have a mutation in the β cardiac myosin heavy chain gene. A.L. is found to have the same mutation, but it is not present in B.L. or C.L. A.L. is started on a program of regular monitoring by echocardiography.

2010



A.L.'s pediatrician learns of a family history of sudden death on his father's side. He arranges for a blood specimen to be sent to the laboratory for a panel of tests involving genes associated with cardiac dysfunction. A.L. is found to have a mutation in the β cardiac myosin heavy chain gene. The same mutation is found in J.L. A.L. is started on a program of monitoring by echocardiography. An echocardiogram done in J.L. reveals signs of advanced hypertrophic cardiomyopathy. He is started on a new β blocker medication, and is advised to consider implantation of a defibrillator.


2015



In the course of a routine primary care visit, D.L. is noted to have a family history of early unexplained death (her mother and maternal aunt). She is tested for a set of risk factors known to predispose to early death and is found to have a mutation in the β cardiac myosin heavy chain gene. She is started on a new class of medication known to prevent the occurrence of hypertrophic cardiomyopathy. Four of her children are also found to carry the mutation. They, too, are started on medication and a program of regular monitoring.

Medical Genetics Training

- Medical Genetics
 - 2 year genetics residency
 - 2 prior years of ACGME-accredited residency
 - 5 year combined internal medicine-genetics or pediatrics-genetics program
 - ACGME-accredited, ABMG certification
- Genetic Counseling
 - 2 years masters program
 - ABGC Certification



Genetics in Medicine

	Primary Care	Specialist	Medical Geneticist
Single Gene or Chromosomal	recognize signs and symptoms; make referral; support family; longitudinal care	manage specific problems	diagnosis; counseling; longitudinal care
Major Gene Multifactorial	Appreciate role of family history; arrange testing and referral to specialist as needed; provide longitudinal care	Diagnosis and management of system-specific problems	Advise on interpretation of test results; genetic counseling; evaluation of complex cases
Complex Multifactorial	Use of genetic tests to guide treatment	Use of genetic tests to guide treatment	Reservoir of knowledge and handling of complex cases

- 
- Education of health professionals and the general public
 - Access to information
 - Tools for screening, education
 - Protection of individual rights and privacy
 - Knowledge of outcomes
 - Development of new prevention strategies and treatments

We tend to overestimate the effect of a technology in the short run and underestimate the effect in the long run.

Amara's Law